BC1618, an Orally Active Fbxo48 Inhibitor, Stimulates Ampk-Dependent Signaling
The adenosine monophosphate (AMP)-activated protein kinase (AMPK) is a central regulator of metabolic pathways. Increasing AMPK activity is an attractive therapeutic target. Fbxo48 is an orphan ubiquitin E3 ligase subunit…